Sodium channel protein type 5 subunit alpha (Nav1.5) and Sodium channel protein type 10 subunit alpha (Nav1.8) (Nav1.5 and Nav1.8)

Voltage-gated sodium channels (Nav) are integral membrane proteins that facilitate the rapid influx of sodium ions into cells, a process essential for the initiation and propagation of action potentials in excitable tissues [3, 11]. Nav1.5, encoded by the SCN5A gene, is the primary sodium channel isoform in the heart and is responsible for the rapid upstroke of the cardiac action potential and coordinated electrical conduction [3, 4]. Dysregulation or genetic mutations in Nav1.5 are linked to life-threatening arrhythmias, including Brugada syndrome and Long QT syndrome type 3 [8, 14]. Nav1.8, encoded by SCN10A, is predominantly expressed in peripheral nociceptive neurons and is a key mediator of pain signaling, particularly in chronic and neuropathic pain states [2, 17]. Interestingly, Nav1.8 has also been identified as a modulator of cardiac rhythm, often co-localizing with Nav1.5 in the heart [1, 9]. Pharmacological targeting of these channels includes traditional non-selective blockers like lidocaine and mexiletine, which are used for both arrhythmias and pain but carry risks of cardiotoxicity and central nervous system side effects [15]. Recent drug development has focused on highly selective Nav1.8 inhibitors, such as suzetrigine (VX-548), to provide effective analgesia without the safety concerns associated with inhibiting other Nav subtypes [6, 10, 19]. These channels represent critical therapeutic targets for managing cardiovascular stability and treating moderate-to-severe pain [5, 12].

Other names

SCN5ASCN10ASodium channel protein type 5 subunit alphaSodium channel protein type 10 subunit alphaCardiac sodium channelSensory neuron-specific sodium channelSNSPN3LQT3Nav1.5Nav1.8

Inhibition of sodium ion influx through the channel pore or allosteric stabilization of the closed state to prevent membrane depolarization and action potential propagation [4, 6, 10].